Regorafenib is effective in the treatment of liver cancer and is indicated for patients with hepatocellular carcinoma who have been previously treated with sorafenib. Regorafenib is a kind of small molecule inhibitor, and in vitro tests show that the drug can inhibit the tumor growth of hepatocellular carcinoma in mice. This shows that the drug is effective against liver cancer, but the drug insert clearly indicates that the drug is suitable for patients with hepatocellular carcinoma who have been previously treated with sorafenib. Adverse reactions to regorafenib are commonly associated with infection, anemia, bleeding, vomiting, nausea, decreased appetite, hyperbilirubinemia, fever, and weight loss. It is important to note that the drug is contraindicated in people who have hypersensitivity reactions to the active ingredients or excipients contained in the drug. The drug is not recommended for children. Nursing women should stop breastfeeding while using the drug. Patients with liver cancer need to be evaluated by a physician before deciding whether or not to use regorafenib and should not use this product privately. For patients with suspected or confirmed liver cancer, it is recommended to go to regular hospitals for evaluation of the condition and follow the doctor’s instructions for treatment to avoid delays.